Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076916 | 0.88 | LMNA (0.62) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL655678 | 0.84 | TP53 (0.62) | CYP3A4TP53ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL28741212 | 0.84 | TSHR (0.54) | CYP3A4TP53ALDH1A1KMT2ALMNA | |
| SCHEMBL29577774 | 0.84 | TP53 (0.62) | CYP3A4TP53ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3968332 | 0.83 | KMT2A (0.50) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10753958 | 0.83 | CYP3A4 (0.59) | CYP3A4TP53ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL7293057 | 0.83 | LMNA (0.72) | CYP3A4TP53ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL31556370 | 0.83 | LMNA (0.72) | CYP3A4TP53ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1491601 | 0.83 | TSHR (0.56) | CYP3A4TP53ALDH1A1LMNATSHR | |
| SCHEMBL345002 | 0.83 | MAPT (0.56) | CYP3A4TP53ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110278-B2 | Selective JAK2 pseudokinase ligands and methods of use | YALE UNIVERSITY (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114521196-A | Bifunctional group degradation agent and use method thereof | 诺华股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | YALE UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | YALE UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| EP-3924333-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113727973-A | Substituted amide compounds useful as farnesoid X receptor modulators | 百时美施贵宝公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
| EP-0900255-B1 | DONOR-SUBSTITUTED OXINDIGO DERIVATIVES AND THEIR USE AS COLOURANTS | CIBA SC HOLDING AG (CH) | 2001-12-19 | — | — | EP | disclosed |
| US-6156914-A | Donor-substituted oxindigo derivatives and their use as colorants | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| US-5922717-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| EP-0900255-A1 | DONOR-SUBSTITUTED OXINDIGO DERIVATIVES AND THEIR USE AS COLOURANTS | Ciba SC Holding AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5700801-A | ANTIINFLAMMATORY AGENTS, BONE DISORDERS | KARL THOMAE, GMBH (DE) | 1997-12-23 | — | — | US | disclosed |
| WO-1997041176-A1 | DONOR-SUBSTITUTED OXINDIGO DERIVATIVES AND THEIR USE AS COLOURANTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1997-11-06 | — | — | WO | disclosed |
| EP-0799202-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996020173-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1996-07-04 | — | — | WO | disclosed |
| EP-0718287-A2 | Piperazine derivatives, medicaments containing them, their use, and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110278-B2 | Selective JAK2 pseudokinase ligands and methods of use | JAK2, JAK1, MCL1 | CYP3A4 4277/4885TP53 2055/4885ALDH1A1 3690/4885 |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | CYP3A4 2539/4885TP53 126/4885ALDH1A1 2189/4885 |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | JAK2, JAK1, MCL1 | CYP3A4 4277/4885TP53 2055/4885ALDH1A1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.